- Home
- IEP vs XENE Comparison
IEP vs XENE Comparison
Compare IEP & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IEP | XENE |
|---|---|---|
| Founded | 1987 | 1996 |
| Country | United States | Canada |
| Employees | 13547 | 370 |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.4B |
| IPO Year | 1994 | 2014 |
Fundamental Metrics
Financial Performance| Metric | IEP | XENE |
|---|---|---|
| Price | $8.22 | $54.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $68.55 |
| AVG Volume (30 Days) | ★ 973.9K | 824.6K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 24.39% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,658,000,000.00 | $311,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.02 | $2,496.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.08 | $28.19 |
| 52 Week High | $9.75 | $62.91 |
Technical Indicators
Market Signals| Indicator | IEP | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 57.60 | 42.85 |
| Support Level | $7.59 | $52.92 |
| Resistance Level | $8.29 | $59.43 |
| Average True Range (ATR) | 0.17 | 1.89 |
| MACD | -0.02 | -0.31 |
| Stochastic Oscillator | 59.62 | 19.62 |
Price Performance
Historical ComparisonAbout IEP Icahn Enterprises L.P.
Icahn Enterprises LP provides diversified business services in the United States. The company operates its business through varied segments which include Investment, Automotive, Energy, Food Packaging, Real Estate, Pharma, and Home Fashion. Among these, the Energy segment derives the maximum revenue from the company. Geographically, it generates maximum revenue from the United States.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.